Peptide researchers are facing a supply chain they no longer recognize. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) met in July 2026 and cast votes on seven research peptides. Those votes now shape what is available — and what isn’t.
A 2023 survey in Drug Testing and Analysis found that nearly 30% of online peptide products tested contained a different compound than the label claimed (Brennan et al., 2023). That’s the real-world backdrop for why this meeting mattered.
If you track compounds like BPC-157, TB-500, or KPV, you now have questions about sourcing, evidence, and next steps. This article breaks down what the PCAC votes mean — and what the research literature says about each compound in plain terms.
What Is the PCAC, and Why Does It Matter?
PCAC is the FDA’s Pharmacy Compounding Advisory Committee. It is a panel of external experts — pharmacists, physicians, toxicologists — who advise the agency on compounding policy.
Compounding refers to custom-prepared drug products made by licensed pharmacies. The FDA regulates two categories under different sections of federal law.
Section 503A covers traditional compounding pharmacies. Section 503B covers “outsourcing facilities,” larger operations that can produce higher volumes.
PCAC’s job is not to approve or reject drugs. It advises on which ingredients may be compounded. Its votes carry real weight because the FDA usually follows its recommendations.
The Problem: A Fragmented Research Supply
Here is the challenge. Seven peptides sat before PCAC in July 2026. Their fates diverge, and the ripple effects hit researchers first.
Some compounds may remain accessible through compounding channels. Others may face tighter restrictions. That uncertainty makes planning experiments — and sourcing quality materials — harder than it should be.
Worse, when legal channels narrow, gray-market suppliers often fill the gap. And as that 2023 testing study showed, what’s on the label isn’t always what’s in the vial.
What the Seven Peptides Are
Before we get to the votes, a quick primer. These are all research peptides, not approved drugs for general use.
BPC-157
BPC stands for “Body Protection Compound.” It’s a synthetic peptide fragment derived from human gastric juice proteins. Preclinical work has examined its role in tissue repair signaling.
TB-500
TB-500 is a synthetic fragment of thymosin beta-4, a protein involved in actin regulation (the cellular scaffolding system). It appears in research focused on cell migration.
KPV
KPV is a tripeptide — three amino acids (Lysine-Proline-Valine) cleaved from alpha-melanocyte-stimulating hormone. Research has looked at it in inflammatory signaling contexts.
MOTS-c
MOTS-c is a mitochondrial-derived peptide. “Mitochondrial” refers to the cell’s energy-producing structures. Studies have explored its metabolic signaling roles.
DSIP
DSIP stands for “Delta Sleep-Inducing Peptide.” Research interest centers on sleep architecture and stress-response modulation.
Semax
Semax is a synthetic analog of ACTH(4-10), a fragment of adrenocorticotropic hormone. It has a research history in neurotrophic (nerve growth-related) pathways.
Epitalon
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide first described in Russian gerontology literature. Research has focused on telomerase activity and melatonin-related pathways.
What the PCAC Votes Signaled
Here’s the takeaway from July 2026. The committee treated these seven compounds case-by-case, but clear themes emerged.
First: the FDA is prioritizing human-use safety data. Compounds with only preclinical or anecdotal support faced sharper scrutiny.
Second: synthetic peptides without approved drug status face an uphill path through Section 503A and 503B compounding.
Third: existing FDA-approved drugs in the same families were treated differently. The agency distinguishes between a compound’s research form and its approved pharmaceutical version.
Let’s take these compound by compound.
BPC-157: Heightened Scrutiny
BPC-157 has long sat in regulatory gray space. The July 2026 vote reinforced the FDA’s concern: no robust human clinical trials support its compounding.
Research suggests BPC-157 may influence growth factor signaling and angiogenesis (new blood vessel formation) in animal models (Chang et al., 2011). But rodent data doesn’t translate directly to human use.
For researchers, the practical implication is this: expect fewer compounding sources. The BPC-157 compound page tracks the current evidence landscape.
TB-500: Similar Headwinds
TB-500 shared BPC-157’s trajectory. The PCAC vote pointed to the same gap: limited published human safety and pharmacokinetic data.
Preclinical studies indicate thymosin beta-4 fragments may support cell motility and tissue remodeling pathways (Smart et al., 2007). But TB-500 itself, as a distinct product, lacks rigorous clinical characterization.
Researchers should treat TB-500 availability as unstable. See our TB-500 compound page for updated research context.
KPV, MOTS-c, DSIP: The Emerging Three
These three peptides are further back in the research pipeline. KPV’s tripeptide structure is simple, but human data remains sparse.
MOTS-c has gained attention in metabolic research. A landmark mouse study suggested mitochondrial-derived peptides play signaling roles in metabolic adaptation (Lee et al., 2015). Translation to humans is still being explored.
DSIP research has oscillated since the 1970s. The PCAC vote didn’t resolve its status but highlighted the need for clearer pharmacology.
Semax and Epitalon: Geographic Context Matters
Semax has an unusual profile. It is approved for use in certain clinical settings in Russia but not by the FDA.
PCAC’s discussion underscored that non-US regulatory approval does not automatically clear US compounding pathways. Researchers should verify sourcing carefully.
Epitalon sits in a similar position. Its literature is concentrated in Eastern European journals, and independent replication in Western research settings remains limited.
What This Means for Your Research Workflow
So where does this leave you? Three practical takeaways.
Sourcing is now a research decision, not just a logistics one. Verify supplier testing and certificates of analysis. Prioritize vendors publishing third-party purity data.
Evidence quality varies sharply across these seven compounds. BPC-157 and TB-500 have deeper preclinical literature than DSIP or Epitalon. Weight your reading accordingly.
Regulatory status is moving. What PCAC recommended in July 2026 may evolve as the FDA issues final guidance. Bookmark this topic and return for updates.
How to Read Peptide Research Going Forward
One more skill worth building: distinguishing research-grade evidence from anecdote.
Preclinical animal studies generate hypotheses. Human randomized controlled trials test those hypotheses. The peptides in this article mostly sit at the hypothesis stage.
When you read a claim, ask: was it tested in humans, at what dose, and with what endpoints? Hedged language — “may,” “suggests,” “indicates” — isn’t a cop-out. It reflects what the data actually supports.
That discipline will serve you well regardless of what PCAC decides next.
Frequently Asked Questions
Did the FDA ban BPC-157 or TB-500?
No outright ban was announced. The PCAC voted on compounding eligibility. That affects pharmacy availability but does not criminalize research possession in every jurisdiction. Check local regulations.
Are these peptides legal to buy for research?
It depends on your country, your stated purpose, and the supplier. Research-use-only products are sold legally in many markets but are not FDA-approved for human use. Verify your local laws before ordering.
What should I look for in a peptide supplier?
Third-party testing documentation, batch-specific certificates of analysis, and transparent sourcing. See our guide to evaluating research peptide vendors for a checklist.
Do these compounds have human clinical trials?
BPC-157 and TB-500 have some limited human data published, mostly in non-Western literature. KPV, MOTS-c, DSIP, Semax, and Epitalon vary widely. Always look for the study population and sample size.
Where can I follow updates on PCAC decisions?
The FDA posts PCAC meeting materials and vote summaries on its official compounding advisory committee page. CompoundGuide will also publish updates as guidance is finalized.
